Investor Home

Corporate Profile

BeiGene is a globally focused biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer. We believe the next generation of cancer treatment will utilize therapeutics both as monotherapy and in combination to attack multiple underlying mechanisms of cancer cell growth and survival...more >

Stock Quotemore >
BGNE (American Depositary Shares)

$66.19

 3.02 (4.36%)

08/18/17  4:00 p.m. ET

Currency is USD
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Press Releasesmore >
BeiGene Announces Pricing of $175 Million Public Offering - August 10, 2017
CAMBRIDGE, Mass. and BEIJING, China, Aug. 10, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage ... Read More
BeiGene Announces Proposed Public Offering - August 9, 2017
CAMBRIDGE, Mass. and BEIJING, Aug. 09, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharm... Read More

Upcoming Events

There are currently no events scheduled.

E-mail Alerts

Sign up to receive e-mail alerts